This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Groves, M. D. Articles by Levin, V. A. Search for Related Content PubMed PubMed Citation Articles by Groves, M. D. Articles by Levin, V. A. Social Bookmarking                            What's this?

Phase II Trial of Temozolomide Plus the Matrix Metalloproteinase Inhibitor, Marimastat, in Recurrent and Progressive Glioblastoma Multiforme

From the Departments of Neuro-Oncology and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Morris D. Groves, MD, M.D. Anderson Cancer Center, Department of Neuro-Oncology, 1515 Holcombe Blvd, No. 431, University of Texas, Houston, TX 77030.

PURPOSE: Novel therapies are needed for patients with recurrent glioblastoma multiforme (GBM). Because there is evidence that temozolomide (TMZ) has some activity in GBM and is well tolerated, and because of laboratory evidence that metalloproteinases are important in glioma cell invasion, the combination of TMZ and the matrix metalloproteinase inhibitor marimastat (MRM) in patients with recurrent GBM was studied.

PATIENTS AND METHODS: Forty-four patients with recurrent GBM after standard radiotherapy were enrolled. For 19 patients, this therapy was their first chemotherapy after tumor progression after irradiation; 25 others had received chemotherapy previously. TMZ 150 to 200 mg/m² days 1 to 5 and MRM 50 mg days 8 to 28 was administered at 28-day intervals for two cycles; then patients were reevaluated. Treatment continued until progression of tumor or toxicity developed.

RESULTS: Joint and tendon pain was the major therapy-related toxicity and was reported in 47% of patients. Five patients (11%) were removed from the study because of intolerable joint pain. For all patients, the progression-free survival (PFS) at 6 months was 39%. Median PFS was 17 weeks, median overall survival was 45 weeks, and 12-month PFS was 16%.

CONCLUSION: The combination of TMZ and MRM resulted in a PFS at 6 months that exceeded the literature target by 29%. This drug combination met phase II study criteria; further study in recurrent patients with GBM might be warranted. Further study of therapy-induced joint pain is necessary.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Antczak, C. Radu, and H. Djaballah A Profiling Platform for the Identification of Selective Metalloprotease Inhibitors J Biomol Screen, April 1, 2008; 13(4): 285 - 294. [Abstract] [PDF]

				P. Hau, D. Koch, T. Hundsberger, E. Marg, B. Bauer, R. Rudolph, M. Rauch, A. Brenner, P. Rieckmann, J. Schuth, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma Neurology, February 27, 2007; 68(9): 688 - 690. [Abstract] [Full Text] [PDF]

				S. Sarkar, R. K. Nuttall, S. Liu, D. R. Edwards, and V. W. Yong Tenascin-C Stimulates Glioma Cell Invasion through Matrix Metalloproteinase-12 Cancer Res., December 15, 2006; 66(24): 11771 - 11780. [Abstract] [Full Text] [PDF]

				N. L. Webster and S. M. Crowe Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases J. Leukoc. Biol., November 1, 2006; 80(5): 1052 - 1066. [Abstract] [Full Text] [PDF]

				M. Stefanidakis and E. Koivunen Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression Blood, September 1, 2006; 108(5): 1441 - 1450. [Abstract] [Full Text] [PDF]

				J. T. Peterson The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors Cardiovasc Res, February 15, 2006; 69(3): 677 - 687. [Abstract] [Full Text] [PDF]

				J. Zhang, S. Sarkar, and V.W. Yong The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase Carcinogenesis, December 1, 2005; 26(12): 2069 - 2077. [Abstract] [Full Text] [PDF]

				J. Nikkola, P. Vihinen, M.-S. Vuoristo, P. Kellokumpu-Lehtinen, V.-M. Kahari, and S. Pyrhonen High Serum Levels of Matrix Metalloproteinase-9 and Matrix Metalloproteinase-1 Are Associated with Rapid Progression in Patients with Metastatic Melanoma Clin. Cancer Res., July 15, 2005; 11(14): 5158 - 5166. [Abstract] [Full Text] [PDF]

				J. R. Goffin, I. C. Anderson, J. G. Supko, J. P. Eder Jr., G. I. Shapiro, T. J. Lynch, M. Shipp, B. E. Johnson, and A. T. Skarin Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3417 - 3424. [Abstract] [Full Text] [PDF]

				C. Giannini, J. N. Sarkaria, A. Saito, J. H. Uhm, E. Galanis, B. L. Carlson, M. A. Schroeder, and C. D. James Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme Neuro-oncol, April 1, 2005; 7(2): 164 - 176. [Abstract] [PDF]

				A. A. Brandes, A. Tosoni, U. Basso, M. Reni, F. Valduga, S. Monfardini, P. Amista, L. Nicolardi, G. Sotti, and M. Ermani Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) J. Clin. Oncol., December 1, 2004; 22(23): 4779 - 4786. [Abstract] [Full Text] [PDF]

				A. A. Brandes, A. Tosoni, P. Amista, L. Nicolardi, D. Grosso, F. Berti, and M. Ermani How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial Neurology, October 12, 2004; 63(7): 1281 - 1284. [Abstract] [Full Text] [PDF]

				W. Wick, J. P. Steinbach, W. M. Kuker, J. Dichgans, M. Bamberg, and M. Weller One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma Neurology, June 8, 2004; 62(11): 2113 - 2115. [Abstract] [Full Text] [PDF]

				A. A. Brandes, U. Basso, M. Reni, F. Vastola, A. Tosoni, G. Cavallo, L. Scopece, A. J. Ferreri, M. G. Panucci, S. Monfardini, et al. First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia J. Clin. Oncol., May 1, 2004; 22(9): 1598 - 1604. [Abstract] [Full Text] [PDF]

				W. J. Bodell, N. W. Gaikwad, D. Miller, and M. S. Berger Formation of DNA Adducts and Induction of lacI Mutations in Big Blue Rat-2 Cells Treated with Temozolomide: Implications for the Treatment of Low-Grade Adult and Pediatric Brain Tumors Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 545 - 551. [Abstract] [Full Text] [PDF]